906 related articles for article (PubMed ID: 30352118)
1. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
Sagiv O; Thakar SD; Kandl TJ; Ford J; Sniegowski MC; Hwu WJ; Esmaeli B
JAMA Ophthalmol; 2018 Nov; 136(11):1236-1241. PubMed ID: 30352118
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitors for Treatment of Metastatic Melanoma of the Orbit and Ocular Adnexa.
Ford J; Thuro BA; Thakar S; Hwu WJ; Richani K; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2017; 33(4):e82-e85. PubMed ID: 27662198
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series.
Finger PT; Pavlick AC
J Immunother Cancer; 2019 Mar; 7(1):83. PubMed ID: 30909967
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
6. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
7. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
8. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
J Cancer Res Clin Oncol; 2019 Feb; 145(2):511-521. PubMed ID: 30539281
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Australian patients receiving non-funded anti-PD-1 immune checkpoint inhibitors for non-melanoma cancers.
Tiu C; Wong A; Herschtal A; Mileshkin L
Asia Pac J Clin Oncol; 2018 Aug; 14(4):337-342. PubMed ID: 29498208
[TBL] [Abstract][Full Text] [Related]
10. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.
Kubo Y; Fukushima S; Inamori Y; Tsuruta M; Egashira S; Yamada-Kanazawa S; Nakahara S; Tokuzumi A; Miyashita A; Aoi J; Kajihara I; Tomita Y; Wakamatsu K; Jinnin M; Ihn H
J Dermatol Sci; 2019 Jan; 93(1):33-40. PubMed ID: 30318169
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
12. The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review.
Moujaess E; Haddad FG; Eid R; Kourie HR
Immunotherapy; 2019 Nov; 11(16):1409-1422. PubMed ID: 31621445
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients.
Ben-Betzalel G; Steinberg-Silman Y; Stoff R; Asher N; Shapira-Frommer R; Schachter J; Markel G
Eur J Cancer; 2019 Feb; 108():61-68. PubMed ID: 30648631
[TBL] [Abstract][Full Text] [Related]
14. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
[No Abstract] [Full Text] [Related]
15. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.
Menzies AM; Johnson DB; Ramanujam S; Atkinson VG; Wong ANM; Park JJ; McQuade JL; Shoushtari AN; Tsai KK; Eroglu Z; Klein O; Hassel JC; Sosman JA; Guminski A; Sullivan RJ; Ribas A; Carlino MS; Davies MA; Sandhu SK; Long GV
Ann Oncol; 2017 Feb; 28(2):368-376. PubMed ID: 27687304
[TBL] [Abstract][Full Text] [Related]
16. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
Ivashko IN; Kolesar JM
Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
[TBL] [Abstract][Full Text] [Related]
18. Use of immune checkpoint inhibitors prolonged overall survival in a Japanese population of advanced malignant melanoma patients: Retrospective single institutional study.
Nakamura Y; Fujisawa Y; Tanaka R; Maruyama H; Ishitsuka Y; Okiyama N; Watanabe R; Fujimoto M
J Dermatol; 2018 Nov; 45(11):1337-1339. PubMed ID: 30204266
[TBL] [Abstract][Full Text] [Related]
19. Association of Inflammatory Markers with Disease Progression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors.
Pan M; Alavi M; Herrinton LJ
Perm J; 2018; 22():17-149. PubMed ID: 29616914
[TBL] [Abstract][Full Text] [Related]
20. Medication use evaluation of programmed death-1 inhibitors in a veteran population.
Nguyen V; Huq M
J Oncol Pharm Pract; 2019 Jul; 25(5):1066-1075. PubMed ID: 29726785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
